December 13, 2018

Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion

GAITHERSBURG, Md., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced updates to its clinical program...
Read more
December 13, 2018

Oncopeptides Capital Markets Day December 14th in New York

Stockholm – December 13, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) will hold its Capital Markets Day in New York tomorrow, Dec 14, between 14:30 – 17:00 CET...
Read more
December 13, 2018

Orexo regains rights to Zubsolv® in all countries outside the US

Uppsala, Sweden – December 13, 2018 - Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the ...
Read more
December 12, 2018

Targovax Presents at DNB 9th Annual Nordic Healthcare Conference

Oslo, Norway, 12 December 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that ...
Read more
December 12, 2018

National Institute for Health and Care Excellence (NICE) issues new guidelines for COPD, Recommending severe patients be evaluated for bronchoscopic lung volume reduction

NICE makes a “strong” recommendation that patients with severe COPD be referred for evaluation for bronchoscopic lung volume reduction, including the Zephyr® Endobronchia...
Read more
December 12, 2018

GenSight Biologics reports sustained quality of life improvements at Week 72 of Phase III REVERSE clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

Composite score and relevant sub-scores in the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) showed sustained improvements at Week 48 and Week 72 Magn...
Read more
December 6, 2018

Orexo hosts Capital Markets Day today in Stockholm, Sweden

Uppsala, Sweden – December 6, 2018 – Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, is today hosting the Co...
Read more
December 5, 2018

CERENIS announces the results of TANGO, a Phase III clinical study evaluating CER-001 in patients with HDL deficiency

 Missed primary endpoint in the TANGO Phase III study, there was no statistically significant difference between the placebo and CER-001 treated groups for the primary outcome ...
Read more
December 5, 2018

Program for Oncopeptides Capital Markets Day December 14th, 2018

Stockholm – December 5, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) have previously announced that they will host a Capital Markets Day in New York. The program...
Read more
December 4, 2018

Nordic Nanovector: Additional preclinical studies with CD37-targeting radioimmunotherapies for B-cell malignancies presented at ASH

Oslo, Norway, 4 December 2018 Nordic Nanovector ASA (OSE: NANO) notes that two new poster presentations from preclinical studies with CD37-targeting radioimmunotherapi...
Read more